ODs face a $32.63 Medicare conversion factor in 2027, plus 80% payment for the lower-cost service when an E/M visit and 0-day ...
Kansas, Tennessee, and Vermont expanded optometric scope in 2026, while vision plan reform and a proposed Medicare fee ...
According to Raphael Rostenne, CTO of EyeCarePro, "anything that takes time" has the potential to frustrate patients, ...
The meeting, which comes a year after the agency issued a complete response letter in October 2025,2 was held from 8:30 am-3 ...
This week’s top stories include pipeline updates in dry eye, retinitis pigmentosa, contact lens hygiene, and more.
The FDA approved Lucamzi (ranibizumab-blrz; Xbrane Biopharma), a biosimilar to Lucentis (ranibizumab; Genentech), for neovascular (wet) age-related macular degeneration (AMD) and ...
What to take away on PBM, hormonal eye health, and GLP-1 receptor agonists from this year’s meeting.
Raphael Rostenne discusses what a good phone call looks like and contributes to successful patient interactions with host ...
Optometry Times delivers clinical news, practice insights, and research updates by optometrists for optometrists to advance care and patient outcomes.
Clinicians may have difficulty in making a diagnosis. Various macular dystrophies can resemble AMD due to the variety of clinical signs and symptoms. Clinicians may find it challenging to ...
FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites. The FDA granted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results